Dyadic International Inc (DYAI) Stock Analysis
Verdict: WATCH (do not buy)
Sub-scale revenue and accelerating cash burn make DYAI a binary bet on pandemic preparedness partnerships amidst a 10-month cash runway.
Investment score: 42/100
Analysis as of
Is Dyadic International Inc stock worth reviewing? The TradeMates thesis
Dyadic is a struggling micro-cap biotech with a promising platform but failing financials. Revenue declined from $3.5M in 2024 to $1.2M in 2025 (pro-forma/estimated), while operating losses remain high. Without a major upfront payment from a partner, the equity face significant dilution risk.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 55/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
Dyadic International Inc opportunities and risks
What speaks for DYAI
- Scripps Research Partnership
What speaks against DYAI
- Imminent Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| DYAI | n/a | 9.5x | n/a | 31.3% | -245.1% | -20.2% |
| SNTI | n/a | 678.2x | n/a | -6134.2% | -135650.0% | -143.8% |
| BIOQ | n/a | 0.7x | 38.0x | -7.0% | -2.9% | 17.7% |
| ALGS | n/a | 7.0x | n/a | 89.0% | -1919.7% | -257.3% |
| NEUP | n/a | n/a | n/a | 101.6% | 263.1% | 207.6% |
| KYNB | 0.3x | 3.8x | 0.2x | 26.7% | 1498.0% | -76.6% |
| Peer median | n/a | 3.8x | n/a | 26.7% | -2.9% | -76.6% |
Frequently asked questions about Dyadic International Inc (DYAI)
Is DYAI stock a good investment?
The TradeMates model rates Dyadic International Inc as WATCH (do not buy) with an investment score of 42/100. Dyadic is a struggling micro-cap biotech with a promising platform but failing financials. Revenue declined from $3.5M in 2024 to $1.2M in 2025 (pro-forma/estimated), while operating losses remain high. Without a major upfront payment from a partner, the equity face significant dilution risk. This is algorithmic model output, not personal investment advice.
Is DYAI stock a buy?
The TradeMates model verdict for DYAI is WATCH (do not buy) with an investment score of 42/100. Treat this as a model signal to review, not a personal buy recommendation.